Product Description
Mechanisms of Action: ADRB Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Hong Kong | Ireland | Korea | New Zealand | Peru | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Huazhong University of Science and Technology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2300070364 | N/A |
Recruiting |
Drug Hypersensitivity |
2024-03-26 |
|
| ChiCTR-IOR-15007571 | N/A |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2016-03-01 |